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Y box protein 1 (YBX1) is a well known oncoprotein that has
tumor-promoting functions. YBX1 iswidely considered to be an
attractive therapeutic target in cancer. To develop novel thera-
peutics to target YBX1, it is of great importance to understand
how YBX1 is finely regulated in cancer. Previously, we have
shown that YBX1 could function as a tumor promoter through
phosphorylation of its Ser-165 residue, leading to the activation
of the NF-B signaling pathway (1). In this study, using mass
spectrometry analysis, we discovered a distinct phosphorylation
site, Ser-176, on YBX1. Overexpression of the YBX1-S176A
(serine-to-alanine) mutant in either HEK293 cells or colon can-
cer HT29 cells showed dramatically reduced NF-B-activating
ability compared with that of WT-YBX1, confirming that Ser-
176 phosphorylation is critical for the activation of NF-B by
YBX1. Importantly, the mutant of Ser-176 and the previously
reported Ser-165 sites regulate distinct groups of NF-B target
genes, suggesting the unique and irreplaceable function of each
of these two phosphorylated serine residues. Our important
findings could provide a novel cancer therapy strategy by block-
ing either Ser-176 or Ser-165 phosphorylation or both of YBX1
in colon cancer.
The Role of YBX1 in Colon Cancer—Y-box binding protein 1
(YBX1) is a multifunctional DNA/RNA-binding protein that
regulates transcription and translation. YBX1 specifically inter-
acts with DNA and RNA and regulates many DNA- and
mRNA-dependent processes, including DNA transcription,
replication, repair, environmental stress, chromatin remodel-
ing, pre-mRNA splicing, etc. (2). High expression of YBX1 is
frequently detected in various cancers, including melanoma,
osteosarcoma, and prostate, breast, squamous cell, lung, ovar-
ian, thyroid, and colon cancer (3, 4), and is closely related to the
progression and poor prognosis of these cancers. For instance,
Shibao et al. (5) first demonstrated that YBX1 expression is
elevated in colon cancer and positively correlates with DNA
topoisomerase II and proliferating cell nuclear antigen
expression. YBX1 can promote tumorigenesis, cell prolifera-
tion, replicative immortality, angiogenesis, invasion, and
metastasis, most of which are the “hallmarks of cancer” pro-
posed by Hanahan and Weinberg (6, 7). It is now widely
accepted that YBX1 is an oncogene. It has been demonstrated
previously that insulin-like growth factor 1 (IGF1)3 activates
the PI3K/AKT pathway, leading to the phosphorylation of Ser-
102 on YBX1 protein and governs its nuclear translocation in
breast cancer cells (8, 9). When this site is disrupted, YBX1 is
unable to translocate to the nucleus and activate the target
genes, leading to reduced tumor growth in human breast can-
cer cells (9–11). In contrast, we recently discovered that, in
response to IL-1 but not IGF1 treatment, YBX1 can be phos-
phorylated on Ser-165 (1), leading to colon cancer progression.
In this study, we have identified distinct Ser-176 phosphoryla-
tion upon treatment with IL-1. We further prove that Ser-176
phosphorylation of YBX1 is critical forNF-B activation and its
tumor-promoting ability. Ser-176 and the previously reported
Ser-165 differentially regulate the expression of different sub-
groups of NF-B target genes, offering a potential mechanism
underlying the finely tuned YBX1-mediated NF-B activation
in colon cancer.
The Role of NF-B in Cancer—NF-B is a family of transcrip-
tion factors that regulate the expression of genes involved in
inflammation, cell proliferation, differentiation, and survival
(12). Constitutively active NF-B has been found in multiple
types of cancer (13, 14). There are five proteins in the mamma-
lian NF-B family: RelA (p65), RelB, c-Rel, p50/p105, and p52/
p100. All proteins in the NF-B family share a Rel homology
domain in their N terminus, which results in their classification
as NF-B/Rel proteins. The Rel homology domain is essential
for dimerization as well as for binding to cognate DNA ele-
ments. The prototypic NF-B is the heterodimer of p65 and
p50. NF-B activity is primarily regulated by interaction with
IB proteins. In most cells, NF-B is present as a latent and
inactive IB-bound complex in the cytoplasm (15).When a cell
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receives an extracellular signal such as stress, cytokines, free
radicals, radiation, etc., IB is degraded, and NF-B rapidly
enters the nucleus and activates target gene expression (16).
Constitutive NF-B has been found in many different types of
cancer (13),makingNF-Bone of themost popular therapeutic
targets in cancer.
Using mass spectrometry analysis, we identified phosphory-
lation of the novel Ser-176 site on YBX1 upon treatment with
IL-1. We showed that overexpression of the S176A-YBX1
(S176A) mutant led to decreased NF-B binding ability and
reduced cell growth and tumorigenic ability compared with the
effect ofWT-YBX1 overexpression.We also demonstrated that
the phosphorylation of Ser-176 and a site reported previously
by our lab, Ser-165 (1), lead to the regulation of quite distinct
groups ofNF-B target genes. Therefore,we propose that phos-
phorylation of Ser-176 on YBX1 is an essential and novel dis-
covery. The functions of phosphorylated Ser-176 or Ser-165 are
not interchangeable and replaceable. This study could provide a
novel therapeutic strategy for controlling the YBX1:NF-B axis
by blocking phosphorylation of either Ser-176 or Ser-165 or
both in colon cancer.
Results
Identification of the Novel Phosphorylation on Ser-176 of
YBX1—Previously, YBX1 was shown to be phosphorylated on
Ser-102 in response to IGF1 in breast cancer cells (9, 10), and,
more recently by us, on Ser-165 upon IL-1 treatment (1). To
determine whether any additional serine sites could be phos-
phorylated by IL-1 stimulation, we conducted further mass
spectrometry analysis in greater detail. Interestingly, we iden-
tified a novel site of phosphorylation onYBX1, Ser-176, in addi-
tion to Ser-165. As shown in Fig. 1, a mass shift of 80 Da was
identified on Ser-176 of the FLAG-tagged YBX1 protein puri-
fied by FLAG pulldown from IL-1-treated 293 (Fig. 1A) and
HT29 cells (Fig. 1B), indicating the existence of a strong phos-
phorylation modification signal on Ser-176.
Phosphorylation of Ser-176 Is Important for the Activation of
NF-B—To determine whether Ser-176 phosphorylation plays
an essential role in the activation of NF-B, we successfully
expressed the S176A mutant at a level comparable with WT-
YBX1 in 293 cells. Meanwhile, a previously generated shYBX1
293 stable cell line was also included for comparison (1) (Fig.
2A). NF-B-specific luciferase assaywas carried out for the cells
described above. As shown in Fig. 2B, upon IL-1 stimulation,
NF-Bwas greatly induced in control 293 cells. Overexpression
of WT-YBX1 dramatically enhanced NF-B activation,
whereas expression of the S176A mutant had considerably
weaker NF-B-activating ability compared with WT-YBX1.
These data suggest that phosphorylation of Ser-176 is critical
for complete activation of NF-B by YBX1.
Phosphorylation of Ser-176 on YBX1 Differentially Regulates
a Subset of NF-B Target Genes—Posttranslational modifica-
tion (PTM) of transcription factors may lead to a different gene
expression pattern (17). To examine this possibility further, we
conducted an Illumina microarray analysis with control 293
cells and WT-YBX1 and S176A overexpression cells. Com-
paredwithWT-YBX1 cells (Fig. 3A), about 35%ofNF-B target
genes were down-regulated by at least 2-fold in cells expressing
S176Amutant protein. About 64% of the genes were not signif-
icantly affected, whereas very few genes (1%) were up-regu-
lated by at least 2-fold. A representative list of NF-B target
genes that were down-regulated by the S176Amutant is shown
in Fig. 3B. These genes can be significantly up-regulated by the
overexpression of WT-YBX1 (WT/Ctrl  2-fold), but their
inductions were dramatically reduced by S176A mutant over-
expression (S176A/WT  0.5). Importantly, among these
genes are cytokines, chemokines, and signaling components
that are involved in tumorigenesis and metastasis, such as
IL-17C, interferon regulatory factor 5 (IRF5), and v-mycmyelo-
cytomatosis viral oncogene homolog 1, lung carcinoma-de-
rived (MYCL1). Several genes, such as IRF5 andMYCL1, were
further confirmedwith qPCR analysis in both 293 cells (Fig. 3C,
top panels) and HT29 cells (Fig. 3C, bottom panels), showing
great reduction in gene expression in the S176A mutant com-
pared with the WT-YBX1 sample under both IL-1-treated or
untreatedconditions.Collectively, thesedataconfirmthatphos-
phorylation of YBX1 at Ser-176 is critical for the activation of a
subset of NF-B-inducible genes.
Ser-176 Is aMajor Phosphorylation Site of YBX1—Previously,
we reported that Ser-165 of YBX1 can be phosphorylated upon
stimulation by IL-1 (1). We wondered whether both Ser-176
and Ser-165 are phosphorylated to a similar extent or whether
FIGURE 1. Identification of phosphorylation of Ser-176 on YBX1. A and B,
mass spectrometry data for YBX1 showing that, in response to IL-1 treat-
ment, Ser-176 is phosphorylated in 293 cells (A) and in HT29 cells (B). A mass
shift of 80 Da was observed, indicating the existence of a phosphorylation
modification. Inset, GelCodeBlue-stainedmass spectrometrygel ofHT29 cells
with the purified YBX1 band marked.
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one is more dominant than the other after IL-1 treatment.
FLAG-tagged WT-YBX1, the S176A single mutant, or the
S176A/S165A double mutant were overexpressed at similar
levels in 293 cells (Fig. 4A). A co-immunoprecipitation experi-
ment was further conducted using anti-FLAG beads, followed
by Western blotting analysis with anti-general phosphorylated
serine antibody. As shown in Fig. 4B, upon treatment with
IL-1, FLAG-WT-YBX1was significantly phosphorylated (Fig.
4B, top panel), whereas the FLAG-S176A mutant exhibited a
dramatically reduced phosphorylation ability compared with
FLAG-WT-YBX1 protein. Furthermore, the FLAG-S176A/
S165A double mutant displayed an even weaker phosphoryla-
tion ability than the FLAG-S176A single mutant, suggesting
that Ser-176 is a more pronounced phosphorylation site than
Ser-165. The intensity of phosphorylation was further quanti-
fied and is shown in Fig. 4B, bottom panel.
Differential and Collaborative Gene Regulation by Phosphor-
ylation of Ser-176 and Ser-165 of YBX1—Because we showed
that both Ser-176 and Ser-165 can be phosphorylated upon
IL-1 treatment, we wondered whether these two sites could
contribute collaboratively or differentially to the NF-B target
gene regulation.Aparallel Illumina array experiment for S165A
was carried out along with the S176A sample. The data suggest
that the expression of33% (185 genes) of NF-B target genes
was reduced by 2-fold or more by S165A mutation (S165A/
WT 0.5) and35% (197 genes) by S176A mutation (S176A/
WT  0.5) (Figs. 3A and 5A, top panel) compared with WT-
YBX1. Among the 197 genes that were down-regulated by
S176A, 82 genes were solely regulated by S176A but not by
S165A (S176A/WT  0.5, S165A/WT  0.5); in other words,
their gene expression is S176A-dependent (Fig. 5A, bottom
panel). On the other hand, among the 185 genes that were
FIGURE 2. Phosphorylation of Ser-176 on YBX1 is critical for its NF-B-
activating ability. A, Western blot showing that YBX1 was overexpressed at
similar levels inWT-YBX1 and the S176Amutant (serine 176-to-alaninemuta-
tion) overexpressing 293 cells. shRNA knockdown of YBX1 expression is also
shown. B, NF-B luciferase assay, showing that overexpression of WT-YBX1
could further enhance IL-1-induced NF-B activation compared with Ctrl,
whereas overexpression of the S176Amutant led to significantly lowerNF-B
activation comparedwithWT-YBX1. Thedata represent themean S.D. from
three independent experiments. *, p 0.05 versus the Ctrl IL-1 group; #,
p 0.05 versus the WT-YBX1 IL-1 group.
FIGURE3.PhosphorylationofSer-176differentially regulates theexpres-
sion of NF-B target genes. A, comparative analysis of the S176A mutant
with WT-YBX1-overexpressing cells on YBX1-inducible NF-B target gene
expression in293cells, showing that35%ofgenesweredown-regulatedby
2-foldormore (S176A/WT-YBX10.5) by theS176Amutation.B, list of typical
NF-B-inducible genes that could be up-regulated by WT-YBX1 (WT) but not
by S176A. The cutoff -fold for induction is 2-fold, whereas, for reduction, it is
0.5 (decreased by 2-fold). C, qPCR analysis showing confirmation of microar-
ray data. Two genes, IRF5 and MYCL1, showed reduced gene expression in
the S176A mutant compared with the WT-YBX1 sample in both 293 (top
panel) and HT29 cells (bottom panel). Furthermore, in IL-1-treated samples,
overexpression of WT-YBX1 significantly increased both IRF5 and MYCL
expression comparedwithCtrl cells. Thedata represent themean S.D. from
three independent experiments. *, p 0.05 versus the Ctrl group; #, p 0.05
versus the Ctrl  IL-1 group; §, p  0.05 versus the WT-YBX1 group; $, p 
0.05 versus the WT-YBX1 IL-1 group.
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down-regulated by S165A, 70 genes were solely regulated by
S165A (S165A/WT  0.5, S176A/YBX1  0.5) but not by
S176A (Fig. 5A, bottom panel); that is, they are S165A-depen-
dent. Beyond the uniqueness of their gene regulation pattern,
both S176A and S165A share the regulation of a common pool
of genes (115 genes) (176A/YBX1  0.5, S165A/WT  0.5),
indicating that they not only differentially regulate distinct sub-
groups of genes but also function in a collaborative manner.
This interesting phenomenon suggests the sophisticated but
elegant gene regulation capacity by the important oncogene
YBX1.
Representative genes that are commonly shared by S176A
and S165A (Fig. 5B, top panel) or solely by S176A (Fig. 5C) or
S165A (Fig. 5D) are shown in Fig. 5. For instance, IRF5 (Fig. 5B)
is regulated by either S176A or S165A. This gene is considered
to be a novel regulator of C-X-C motif chemokine ligand 13
(CXCL13) expression in cancer (18). In contrast,MYCL1 (Fig.
5C) is solely regulated by S176A. MYCL1 is a member of the
MYC gene family, which is well known for its oncogenic poten-
tial or correlation with poor prognosis in cancer (19). For
S165A-regulated genes, oncostatin-M (OSM) is a very good
example. This gene encodes a member of the leukemia inhibi-
tory factor/OSM family of proteins. OSM protein is a secreted
cytokine that may regulate the production of other cytokines,
including IL6, G-CSF, and GM-CSF in endothelial cells. The
OSM receptor is suggested to be a novel therapeutic target in
cancer (20). A full list of each group of genes is provided in
supplemental Tables S1–S3.
To identify the signature networks of each subgroup of
genes, we further conducted an ingenuity pathway analysis
(IPA). It is extremely interesting that we observed that each
group of genes is associated with quite distinct network func-
tions. For instance, the commonly regulated genes by both
S176A and S165A are predominantly associated with network
functions of “protein degradation, synthesis, and cellular func-
tion and maintenance” (Fig. 5B, bottom panel) and “cellular
development, cellular growth and proliferation, and connective
tissue development and function” (supplemental Table S4 and
Fig. S1). Although S176A solely regulated genes are associated
with network functions of “cancer, dermatological diseases and
conditions, and gastroenterological diseases” (Fig. 5C, bottom
panel) and “cancer, hematological diseases, and hereditary dis-
orders” (supplemental Table S5 and Fig. S2). In great contrast,
S165A solely regulated genes are mainly involved in the net-
work functions of “cell morphology, cell death and survival, and
reproductive system development and function” (Fig. 5D, bot-
tom panel) and “cell-to-cell signaling and interaction, nervous
system development and function, and developmental disor-
ders” (supplemental Table S6 and Fig. S3). Strikingly, NF-B is
one of the most pivotal nodes in each of the key networks (Fig.
5, B–D, bottom panels). Importantly, YBX1 also shows up in
two of these networks (Fig. 5,C andD, bottom panels), suggest-
ing an intimate yet sophisticated connection between YBX1
and NF-B. In short, the above evidence inarguably supports
the important and distinct role of differential gene regulation
by phosphorylation of Ser-176 and Ser-165 of the YBX1
protein.
Phosphorylation of Ser-176 on YBX1 Plays an Important Role
in Cell Proliferation and Anchorage-independent Growth in
Colon Cancer Cells—Because NF-B is well known to be
involved in the expression of factors that can promote cancer
cell proliferation, we decided to examine the effects of the
S176A mutant on NF-B activity, cell proliferation, and an-
chorage-independent growth in HT29 colon cancer cells. We
established stable HT29 cell lines either with the overexpres-
sion ofWT-YBX1 or with S176A (Fig. 6A, top panel). By carry-
ing out NF-B-specific luciferase reporter assays, we further
confirmed that overexpression of WT-YBX1 could activate
NF-B, as we observed previously (1) (Fig. 6A, bottom panel).
Furthermore, we proved that the S176A overexpression cells
had lower NF-B luciferase activity compared with the WT-
YBX1 overexpression cells, confirming that S176A plays an
FIGURE 4.Ser-176 is amajor phosphorylation site of YBX1.A, Western blot
showing that FLAG-taggedWT-YBX1, S176A, and S176A/S165Awere overex-
pressed at similar levels in 293 cells. Anti-YBX1 antibody was used to detect
the total YBX1 expression.-Actinwas probed as a loading control. B, Ser-176
is a major phosphorylation site on YBX1. Top panel, co-immunoprecipitation
and Western blot of 293 control cells and cells containing FLAG-tagged WT-
YBX1, S176A, or S176A/S165A. These cells were treated with IL-1 for 1 h or
left untreated. FLAG-tagged YBX1 was further pulled down with anti-FLAG
beads and subjected to Western blotting analysis using an anti-phospho-
serine motif antibody. The inputs were probed with an anti-YBX1 antibody.
The Western blot shows that FLAG-tagged WT-YBX1 could be significantly
phosphorylated upon IL-1 stimulation, whereas FLAG-S176A mutation
abolished most of the phosphorylation effect on YBX1, and FLAG-176A/
S165A double mutation led to even weaker YBX1 phosphorylation. Bottom
panel, quantitative analysis of the phosphorylation signal in the top panel,
showing that, in response to IL-1 treatment, Ser-176 is an important phos-
phorylation site on YBX1. IB, immunoblot.
Ser176 Phosphorylation of YBX1 Activates Colon Cancer NF-B
3436 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 292•NUMBER 8•FEBRUARY 24, 2017
important role in regulating NF-B activity. Additionally, we
determined the effect of S176A on cell proliferation. As shown
in Fig. 6B, top panel, overexpression of WT-YBX1 promoted
cell growth compared with HT29 control cells, whereas over-
expression of S176A showed a significantly reduced cell prolif-
eration ability compared with WT-YBX1 overexpression cells,
suggesting that phosphorylation of Ser-176 of YBX1 is impor-
tant for its cell proliferation ability.
To test the effect of Ser-176 on anchorage-independent
growth, a soft agar assay was performedwith the cells described
above. As shown in Fig. 6B, center panel, overexpression of
WT-YBX1 enhanced colony sizes comparedwithHT29 control
cells, whereas overexpression of S176A showed a much
reduced colony-forming ability compared with WT-YBX1.
Together, these data suggest that Ser-176 phosphorylation of
YBX1 is very important for promoting anchorage-independent
growth.
To achieve a cleaner effect of the S176Amutant, we used the
shYBX1 (3-UTR) construct to knock down the endogenous
YBX1 in either HT29 or HCT116 colon cancer cells and then
reconstituted these cells with similar levels of WT-YBX1 or
S176A protein (Fig. 6, C and D, top panels). Cell proliferation
and anchorage-independent growth assays were carried out.
The data suggested that stable cell lines of shYBX1 (3-UTR)
infected with S176A virus, hereafter referred to as S176A put-
back cells, behavedmore like the shYBX1 (3-UTR) cells, show-
ing a slower cell growth rate and weaker colony formation abil-
ity in both HT29- and HCT116-derived cells (Fig. 6, C and D).
In contrast, stable cell lines of shYBX1 (3-UTR) infected with
WT-YBX1 virus, hereafter referred to as WT-YBX1 put-back
cells, showed similar properties as the parental HT29 (Fig. 6C)
or HCT116 cells (Fig. 6D). Together, the above data confirm
that Ser-176 is an important site to promote colon cancer
progression.
Activation of NF-B by YBX1 Ser-176 PhosphorylationWorks
Independently of IBDegradation—As IB degradation is an
important step in the activation of NF-B by cytokines such as
IL-1, we wondered whether the decreased NF-B-activating
ability by S176A is due to its effect on the process of IB
degradation. Both 293- or HT29-derived cells with WT-YBX1
or S176A overexpression were treated with IL-1 for different
times (Fig. 7, A and B). The degradation of IB was further
determined byWestern blotting analysis. The data indicated no
significant difference in IB degradation among different cell
FIGURE 5. Phosphorylation of Ser-176 or Ser-165 results in differential expression of a subgroup of NF-B target genes. A, comparative analysis of the
S176A mutant with the S165A mutant on YBX1-inducible NF-B target gene expression. The pie chart shows that, although the S176A and S165A mutants
shared the regulation of 115 genes, each also had its own pool of solely regulated genes, with S176A regulating 82 unique genes and S165A regulating a
completely different set of 70 genes. B, top panel, a short list of representative NF-B-inducible genes that were down-regulated by both S176A and S165A
mutants. Bottom panel, IPA showing that genes commonly regulated by both S176A and S165A are associated with a network of the functions of “protein
degradation, synthesis, and cellular function and maintenance.” Importantly, NF-B is one of the critical nodes in this network. C, top panel, a short list of
representative NF-B-inducible genes that were down-regulated solely by the S176A mutant. Bottom panel, IPA showing that the genes solely regulated by
S176A are associatedwith a network of the functions of “cancer, dermatological diseases and conditions, and gastroenterological diseases.” Importantly, both
NF-B and YBX1 are critical nodes in this network.D, top panel, a short list of representative NF-B-inducible genes that could be down-regulated solely by the
S165Amutant. Bottom panel, IPA showing that genes solely regulated by S165A are associatedwith a network of the functions of “cell morphology, cell death
and survival, and reproductive system development and function.” Importantly, both NF-B and YBX1 are critical nodes in this network.
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lines, confirming that phosphorylation of Ser-176 had no obvi-
ous effect on IB degradation. We then tested whether phos-
phorylation of Ser-176 of YBX1 affected NF-B DNA binding
ability. A B-specific EMSA was carried out in 293 and HT29
cells with the overexpression of WT-YBX1 or S176A mutant
(Fig. 7C). Previously, we and others have verified that prototyp-
ical NF-B (p65/p50 heterodimer) DNA binding ability could
be dramatically induced after treatment with IL-1 (1, 12, 13).
We now show that overexpression of WT-YBX1 further
enhanced IL-1-induced B binding activity, whereas S176A
mutation had a much lower NF-B DNA binding ability com-
paredwith theWT-YBX1 overexpression cells. These data sug-
gest that Ser-176 phosphorylation is necessary for YBX1 to
modulate NF-B DNA binding activity.
We also wondered whether IL-1 induces the binding of
YBX1 to NF-B. To examine this possibility, 293 cells or HT29
cells co-expressed with FLAG-p65 (the subunit of NF-B) (1)
andMyc-WT-YBX1 (Fig. 7D) were established and used as the
experimental models. Upon treatment with IL-1 for 1 h, we
observed increased binding of Myc-WT-YBX1 to FLAG-p65,
suggesting that IL-1 may induce the binding of YBX1 to
NF-B, leading to YBX1-enhanced NF-B activation.
Localization of YBX1 Is Dependent on Ser-176 Phosphor-
ylation—YBX1 nuclear shuttling has been associated with
increased tumor promoter activity. We therefore examined
whether phosphorylation at Ser-176 is important for nuclear
translocation of YBX1.We carried out an immunofluorescence
(IF) experiment with a specificmonoclonal antibody for FLAG-
tagged YBX1 in our FLAG-WT-YBX1 and FLAG-S176A over-
expression 293 or HT29 cells. As shown in Fig. 8, upon treat-
ment with IL-1, FLAG-WT-YBX1 was localized to both the
cytoplasm and nucleus, whereas the FLAG-S176A mutant
exhibited a different pattern by localizing only to the cytoplasm
(Fig. 8). These data suggest that Ser-176 phosphorylation is
necessary for nuclear translocation of YBX1.
Ser-176 Phosphorylation Is Critical for Cytokine Secretion in
Colon Cancer Cells—Activation of NF-B is associated with the
release of many different cytokines from cells. Therefore, we
decided to examine the effects of the S176Amutant on cytokine
secretion profiles. Conditioned medium was collected from
FIGURE6.Phosphorylationof Ser-176ofYBX1plays a crucial role inpromoting cell proliferationandanchorage-independentgrowth inhumancolon
cancer cells.A, toppanel,Westernblot showing thatoverexpressionofWT-YBX1or theS176Amutantwasat similar levels inHT29cells.Bottompanel, luciferase
assay showing that WT-YBX1 activated NF-B, whereas the S176Amutation impaired the ability of YBX1 to activate NF-B. *, p 0.05 versus the Ctrl group; #,
p 0.05 versus the WT-YBX1 group. B, top panel, cell growth curve showing that overexpression of WT-YBX1 promoted cell growth compared with the Ctrl
group, whereas using a pool of shRNA to knockdown YBX1 greatly slowed down cell growth. Moreover, the S176A mutation led to decreased cell growth
compared with WT-YBX1 cells. *, p  0.05 versus the Ctrl group; #, p  0.05 versus the WT-YBX1 group. Center and bottom panels, anchorage-independent
growth (soft agar) assay showing WT-YBX1 cells exhibited increased colony size compared with Ctrl cells. S176A mutant cells showed decreased colony size
compared with WT-YBX1 cells. Furthermore, YBX1 shRNA knockdown led to decreased colony size compared with the Ctrl group. *, p 0.05 versus the Ctrl
group; #, p  0.05 versus the WT-YBX1 group. C and D, first panels, Western blots showing that WT-YBX1 and S176A were expressed at similar levels as the
parental HT29 cells (C) or HCT116 cells (D) in put-back cells (into their shYBX1 (3-UTR) cells, respectively). Secondpanels, cell growth curves showing that S176A
put-back cells displayed a similar cell growth rate as shYBX1 (3-UTR) cells, whereas WT-YBX1 put-back cells completely rescued cell growth rate and showed
similar cell growth rates as their parental HT29 cells (C) or HCT116 cells (D). *, p 0.05 versus the parental cell group. Third and fourth panels, S176A put-back
cells and shYBX1 (3-UTR cells) had significantly reduced colony formation abilities compared with either parental HT29 cells (C) or HCT116 cells (D) or their
WT-YBX1 put-back cells. * p 0.05 versus the parental cell group.
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HT29 cells with either WT-YBX1 or S176A mutant overex-
pression. A cytokine ELISA array was further carried out in
triplicate to determine the secretion of different cytokines and
growth factors. As shown in Fig. 9, most factors showed
reduced secretion in the S176Amutant line compared with the
WT-YBX1 sample, whereas there was an overall increase in
cytokine expression in the WT-YBX1 line compared with the
control. Specifically, secretion of cytokines such as IL-2, VEGF,
TNF, and PDGF was reduced in the S176Amutant compared
with the WT-YBX1 sample. Importantly, these cytokines and
growth factors are known to be involved in cell proliferation
and growth pathways. Overall, our data suggest that Ser-176
phosphorylation is critical for certain cytokines to be secreted
into the colon cancer microenvironment.
Hypothetical Model of Differential Phosphorylation of YBX1
on Ser-176 and Ser-165 and Their Roles in NF-B Activation—
By using the Human Protein Reference Database, we suggest
casein kinase I (CKI) as a potential kinase that would phosphor-
ylate Ser-176 on YBX1 (Fig. 10A). To determine the role of CKI
in YBX1 phosphorylation, we used a pool of shCKI constructs
to knock down the expression of CKI in FLAG-WT-YBX1-
overexpressing 293 cells (Fig. 10B, top panel). These cells were
further treated with IL-1, followed by co-immunoprecipita-
tion experiment using anti-FLAG beads. Phosphorylation of
YBX1 was further detected by Western blotting analysis using
an anti-phospho-serine antibody. The data (Fig. 10B, bottom
FIGURE 7. Activation of NF-B by YBX1 Ser-176 phosphorylation works
independently of IB degradation. A and B, Western blots in 293 (A) and
HT29 cells (B) showing that there is no significant difference for the degrada-
tion pattern of IB after IL-1 treatment among Ctrl, WT-YBX1, and S176A
mutant cells. C, EMSA assay showing that overexpression of WT-YBX1
enhanced NF-B (mainly p65/p50 heterodimer) DNA binding ability com-
pared with Ctrl in both 293 (left panel) and HT29 cells (right panel), whereas
the S176A mutant showed decreased NF-B DNA binding ability compared
with WT-YBX1. IL-1-induced (30-min treatment) NF-B binding in Ctrl cells
served as the positive control, which has beenpublishedpreviously (1, 12, 13,
36, 37). D, top panel, co-immunoprecipitation (IP) experiments in 293 cells
with or without co-expression of Myc-tagged WT-YBX1 and FLAG-tagged
p65. These cells were treated with IL-1 for 1 h or left untreated. FLAG-p65
was thenpulleddownwith anti-FLAGbeads. Sampleswere then subjected to
Western blotting analysis (immunoblotting, IB) and probed with anti-Myc
antibody to detect the co-immunoprecipitation of Myc-WT-YBX1. The data
indicated that IL-1 treatment enhanced the interaction between Myc-WT-
YBX1 and FLAG-p65 when both Myc-WT-YBX1 and FLAG-p65 were co-ex-
pressed. For inputs, anti-Myc antibody was used to detect Myc-WT-YBX1,
anti-YBX1 antibodywas used to show the input of total YBX1, anti-FLAG anti-
body was used to detect the input of FLAG-p65, and anti-p65 antibody was
used to show the input of total p65. Bottom panel, similar experiments were
done in HT29 cells and showed similar results. The conditions and denota-
tions are same as in the top panel.
FIGURE 8. Localization of YBX1 is dependent on Ser-176 phosphoryla-
tion. Immunofluorescenceexperiment showing localizationof nuclei stained
with Hoechst (blue) and FLAG-tagged YBX1 (green) with an anti-FLAGmono-
clonal antibody. FLAG-WT-YBX1 exhibited localization to both the cytoplasm
and nucleus, with more being localized in the nucleus upon IL-1 treatment
in both 293 (left panel) andHT29 cells (right panel) containing FLAG-WT-YBX1
overexpression. On the other hand, the FLAG-S176Amutant exhibited local-
ization mainly to the cytoplasm but not the nucleus, even after treatment
with IL-1. Images were taken at 63with a fluorescence microscope.
FIGURE 9.Ser-176phosphorylation is critical for cytokine secretion.Cyto-
kine array experiment showing that conditioned medium from WT-YBX1
overexpression cells displayed higher secretion of cytokines and growth fac-
tors comparedwith HT29 control cells, whereasmedium fromS176A-overex-
pressing cells displayed much lower amounts of secretion of most cytokines
than WT-YBX1 cells. Experiments were conducted in triplicate. *, p  0.05
versus Ctrl; #, p 0.05 versusWT-YBX1.
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panel) indicated that, although IL-1 could induce the phos-
phorylation of YBX1 (this is consistent with what we observed
in Fig. 4B), knockingdownCKI largely abolished this phosphor-
ylation effect. As we suggested before (Fig. 4B), Ser-176 is the
predominant phosphorylation site on YBX1. Thus, based on
the data we have presented, we propose that, in the presence of
an activating cytokine such as IL-1, the IB kinase phosphor-
ylates IB, which leads to the degradation of IB. While this
is occurring, IL-1 can activate CKI, leading to the phosphory-
lation of YBX1 on Ser-176.Meanwhile, CKII is activated in paral-
lel, which can promote phosphorylation of YBX1 on Ser-165 (1).
These two different phosphorylation events on YBX1 can activate
NF-B, leading to the regulation of either some common pool or
different subgroups of NF-B-inducible genes, resulting in finely
tuned NF-B driven functions (Fig. 10C).
Discussion
PTM is one of the key approaches that mammalian cells use
to control gene expression and cellular functions in a sophisti-
catedmanner (21, 22). One well known example is the PTMs of
NF-B, in which over a dozen different phosphorylation sites
were identified either in response to different stimuli or in dif-
ferent cell systems (23–25).
Compared with the study of NF-B, the understanding of
PTMs of the important oncoprotein YBX1 is far less developed.
In this study, we provide strong evidence regarding the discov-
ery of the novel phosphorylation of Ser-176 on YBX1.We show
that the S176Amutant exhibits decreased activation of NF-B,
reduced secretion of cytokines such asVEGF, IL-12, andTNF,
decreased cell proliferation ability, and compromised anchor-
age-independent growth capacity. Furthermore, S176Amutant
protein is mainly restricted to the cytoplasm, whereas WT-
YBX1 is located in both the cytoplasm and nucleus, indicating
the importance of Ser-176 phosphorylation for YBX1 translo-
cation to the nucleus. Importantly, the gene regulation levels
show that phosphorylation of Ser-176 is critical for the expres-
sion of a number of NF-B-inducible genes. Both Ser-176 and
Ser-165 phosphorylation differentially or collaboratively regu-
FIGURE 10.Hypotheticalmodel of differential phosphorylation of YBX1 on Ser-176 and Ser-165 and their role in NF-B activation. A, prediction of the
phosphorylation site by CKI on YBX1 at Ser-176 using the Human Protein Reference Database. B, top panel, Western blot showing that CKI protein was
successfully knocked downwith a pool of shCKI constructs in 293 stable cells containing FLAG-WT-YBX1 (cell line from Fig. 4A). Bottom panel, co-immunopre-
cipitation (IP) experiment and Western blot showing that, using the above cells, FLAG-tagged WT-YBX1 was pulled down with anti-FLAG beads and then
probed with anti-phospho-serine antibody. shCKI cells showed dramatically reduced serine phosphorylation on FLAG-WT-YBX1 upon IL-1 treatment com-
pared with control cells. IB, immunoblot. C, hypothetical model showing that, in the presence of stimuli of the NF-B pathway such as IL-1, IB kinase
phosphorylates IB, causing degradation of IB. The free p65/p50 heterodimer thenmigrates to the nucleus to bind to B-binding sites on the promoters of
specific genes, leading to their activation.While this is occurring, IL-1 can also stimulate YBX1 by activating CKI, which then leads to phosphorylation of YBX1
on Ser-176, and by activating CKII, which can promote phosphorylation of YBX1 on Ser-165 (1). These two different phosphorylation events either regulate
some common pool of NF-B-inducible genes or independently regulates quite distinct subgroups of NF-B-inducible genes, leading to plasticity of NF-B-
driven biological functions.
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late different subgroups of genes that are associated with differ-
ent networks of functions (Fig. 5, B and D). Collectively, the
evidence provides deep insights into how PTMs of YBX1 regu-
late different cellular functions.
Not surprisingly, the two serine/threonine protein kinases
that we proposed in this study, either CKI or II, have been
linked to carcinogenesis and its related processes (26–28). It
was reported that the highly conserved and ubiquitously
expressed pleiotropic CKI family plays critical regulatory roles
in many cellular processes, including DNA processing and
repair, proliferation, and cell differentiation. Furthermore, CKI
is tightly involved in the regulation and degradation of p53,
mouse double minute, and -catenin. In addition, CKI also can
phosphorylate and activate Wnt signaling (29). It is important
to note that Wnt is known to play an important role in the
epithelial-mesenchymal transition (EMT), an important pro-
cess that contributes to cancer development (30). Interestingly,
YBX1 has also been implicated in interacting with promoters of
a number ofWnt pathway proteins (31).Mutations and genetic
alterations of CKI are often detected in various cancers. There-
fore, CKI is considered a highly attractive therapeutic target in
cancer (32). On the other hand, although belonging to a differ-
ent family, CKII is also involved in various important cellular
processes, including cell cycle control, apoptosis, and circadian
rhythm. It is well known that CKII plays an important role in
tumorigenesis and angiogenesis processes (33, 34). In this
study, we suggest that Ser-176 is a more predominant phos-
phorylation site on YBX1 than Ser-165. Therefore, CKI poten-
tially plays a more significant role than CKII in the systems we
studied.
As proposed in our model, both Ser-176 and Ser-165 (1) are
critical for the nuclear translocation of YBX1 and its ability to
enhance NF-B binding to DNA. However, details are still
unknown regarding the exact order of these phosphorylation
events. In the future, it would be important to further study the
role of CKI in Ser-176 and CKII in Ser-165 phosphorylation.
This endeavor may provide a better understanding of the intri-
cacies of communication between the YBX1 andNF-B signal-
ing pathways that are linked throughSer-176 andSer-165 phos-
phorylation on YBX1. Additionally, how exactly YBX1 may
enhance NF-B binding to DNA is still unknown. Based on our
EMSA data (Fig. 7C), we speculate that at least the phosphory-
lation of Ser-176 and Ser-165 (1) is critical to this process. Fur-
thermore, the IF data (Fig. 8) also affirmed that lack of phos-
phorylation of Ser-165 (1) and Ser-176 could lead to the
retention of most YBX1 into the cytoplasm and prevent it from
translocating into the nucleus. In the future, studies such as
chromatin immunoprecipitation experiments and in silico
crystal structure prediction of the binding between YBX1 and
NF-B may help us to better understand this important aspect
of YBX1-mediated NF-B activation.
Furthermore, the discovery of Ser-176 phosphorylation of
YBX1 and its link to NF-B activation is significant. Although
bothNF-B and YBX1 are known to play critical roles in cancer
progression, the interaction between YBX1 and NF-B is still
understudied. Interestingly, NF-B is one of the very few criti-
cal nodes in the three networks of functions we proposed (Fig.
5, B–D). More importantly, YBX1 also serves as a critical node
in two of these three networks, suggesting that the crosstalk
between YBX1 and NF-B is critical and complicated. Phos-
phorylation sites such as Ser-176 and Ser-165 of YBX1 and their
different regulatory abilities on NF-B target genes are there-
fore of particular importance in terms of increasing our knowl-
edge of the connection between the YBX1 andNF-B signaling
pathways.
Notably, YBX1 is an excellent example of how a novel NF-B
modulatormay regulateNF-B and its downstream target gene
expression. The concept of protein modulators of RelA, i.e. the
p65 subunit ofNF-B, has been developed previously by Li et al.
(35) with computational approaches (35). In their report, the
authors provided a repertoire of near 600modulators for exper-
imental validation. They further hypothesized that these RelA
modulators might influence the expression of “certain groups”
of NF-B-dependent genes. Remarkably, one of their predicted
novel modulators was YBX1. Although a complete mystery at
that time, this study has inarguably validated the role of YBX1
as a novelNF-Bmodulator and unveiled the underlyingmech-
anism of how YBX1 may regulate NF-B and lead to the acti-
vation of certain groups of its target genes. Therefore, this study
is of great novelty and significance.
In a broader scope, a fascinating aspect regarding the novel
phosphorylation of Ser-176 and Ser-165 of YBX1 could be its
potential influence on the overall YBX1 functions. For instance,
YBX1 is well known for playing an important role in translation
control. Evdokimova et al. (36) demonstrated that YBX-1 reg-
ulated EMT by inducing cap-independent translation of EMT-
promoting factors and suppressing cap-dependent translation
of growth-promoting factors, confirmingYBX-1 as a restriction
point of EMT. Interestingly, NF-B is famous for being a key
player in EMT gene regulation (37). In the future, it would be of
immense interest to explore whether phosphorylation of Ser-
176 and Ser-165 on YBX1 may play any role in translational
control of EMT genes as well as other important functions of
YBX1.
Finally, this research may provide a potential therapeutic
approachincoloncancer treatment.TargetingYBX1phosphor-
ylation may lead to the inhibition of NF-B activity in cancer,
providing a more specific therapeutic approach than targeting
NF-B itself in general. In the future, it would be very interest-
ing to explore whether phosphorylation of Ser-176 and Ser-165
of YBX1 could be generalized to some other types of cancer
beyond colon cancer, therefore providing novel therapeutic
approaches to other types of cancer as well.
Experimental Procedures
Cell Lines and Antibodies—The 293 cell line has been
described previously (38). TheHT29 andHCT116 colon cancer
cell lines were purchased from the ATCC (Manassas, VA) and
cultivated in RPMI 1640 medium with 100 units/ml penicillin,
100 g/ml streptomycin, and 10% fetal calf serum. The follow-
ing antibodies were obtained from commercial sources: anti-
YBX1 (Abcam, Cambridge, MA), anti-IB and anti-CKI
(Santa Cruz Biotechnology Inc., Dallas, TX), anti--actin (Sig-
ma-Aldrich, St. Louis, MO), and anti-phosphorylated serine
and anti-Myc (Cell Signaling Technology, Danvers, MA).
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Construction of Stable Cell lines—FLAG-tagged WT-YBX1
cDNAwas amplified by reverse transcription from totalmRNA
derived from 293 cells. The sequence was confirmed and then
cloned into the pLVX-IRES-puro vector (1). Mutations of the
Ser-176 residue to Ala (S176A) or S176A/S165A were gener-
ated using the QuikChange II XL site-directed mutagenesis kit
following the protocol of the manufacturer (Agilent Technolo-
gies, Inc., Santa Clara, CA). The mutated site was then con-
firmed by sequencing. The shRNA pool against YBX1 was pur-
chased from Sigma-Aldrich. All cell lines were generated using
either 293, HT29, or HCT116 colon cancer cell lines. To gen-
erate stable cell lines, the lentiviral plasmid containing theDNA
of interest or shRNAs targeting either exon or 3-UTR (for put-
back expression) of YBX1 or CKI were transfected into a 293T
packaging cell line to produce viruses. 293, HT29, or HCT116
cells were then infected with these viruses and further selected
with 1 g/ml of puromycin, as the lentiviral vector construct is
comprised of a puromycin resistance gene. Expression of the
respective constructs was confirmed using Western blotting
with specific antibodies. For stable YBX1 put-back cells, stable
shYBX1–3-UTR cells were first established. The same num-
bers of these cells under the same conditionswere then infected
with the same titers of viruses for either WT-YBX1 or the
S176A mutant. Cells were then selected under either 0.5 or 1
g/ml puromycin. Two stable pools per cell line were collected.
Samples were then examined byWestern blotting analysis, and
cells with comparable YBX1 expression (parent, WT-YBX1,
and S176Amutant cells) were used for both cell growth and soft
agar experiments.
Transfections and Luciferase Assays—Constructs were trans-
fected into cell lines using the Lipofectamine and PLUS re-
agents (Life Technologies/Invitrogen). For NF-B luciferase
assays, the B-luciferase construct p5XIP10 B (39) was trans-
fected transiently into the cells, and luciferase activity was
determined 48 h later. A -galactosidase construct was co-
transfected to normalize for transfection efficiency. Transfec-
tions and luciferase assays were carried out as described previ-
ously (39).
Western Analyses—Cells were cultured to95% confluence,
and samples were collected and assayed byWestern blotting as
described previously (39). Different antibodies were used based
on different experiments as described in the text.
Co-immunoprecipitations—Cells cultured in 10-cm plates to
95% confluency were lysed in co-immunoprecipitation buffer
(1%TritonX-100 (v/v), 50mMTrisHCl (pH7.4), 150mMNaCl,
1 mM EDTA, 1 mM sodium orthovanadate, 20 M aprotinin, 1
mM phenylmethanesulfonyl fluoride, and 1 mM pepstatin A).
Prewashed anti-FLAG-M2 antibody, EZView beads were
(Sigma)mixedwith cell lysates with equivalent amounts of pro-
tein at 4 °C overnight. Gel beads were washed four times with
co-immunoprecipitation buffer with rotation at 4 °C for 5 min
each time. For the last step, FLAG peptide was added to elute
the FLAG-tagged protein. Samples were added to SDS sample
loading buffer (6% (v/v) glycerol, 1% (v/v) -mercaptoethanol,
2% (w/v) SDS, 50mMTrisHCl (pH6.7), 0.004% (w/v) bromphe-
nol blue), and we further proceeded with Western blotting
analysis as described above.
EMSA—The oligomer used for NF-B binding site was
5AGTTGAGGGGACTTTCCCAGGC-3 (Santa Cruz Bio-
technology, Inc.). It was labeled with [-32P]ATP by the poly-
nucleotide kinase method, following the protocol provided by
Promega Corp. (Madison, WI). Whole cell lysates were pre-
pared and analyzed as described previously (1).
Cell Growth and Soft Agar Assays—HT29 cells overexpress-
ingWT-YBX1, S176A, and shRNA-YBX1 knockdown cell lines
were plated at 2  104 cells/well in a 6-well plate with 3 ml of
RPMI 1640 medium. Cells were seeded in triplicate and
counted on different days using a cell counting chamber. For
soft agar assays, type VII agarose (Sigma) was autoclaved and
mixedwith RPMI 1640 cell growthmedium. Cell culture dishes
were coated with 1.2% type VII agarose as the bottom layer.
Cells were resuspended in 0.6% of type VII agarose and plated
on top of the bottom layer. Cells were cultured for 2–3 weeks
before being checkedunder amicroscope,measured, andquan-
tifiedwith the aid of ImageJ software (http://imagej.nih.gov/ij/).
Preparation of Samples for MS Experiments—Ten 15-cm
plates of 293 or HT29 cells with the stably expressed FLAG-
tagged WT-YBX1 protein were cultured to 80% confluence.
Fivewere used as controls, and the other five plateswere treated
with IL-1 for 1 h. Cells were then lysed with co-immunopre-
cipitation buffer (see “Co-immunoprecipitations”). After spin-
ning the debris for 10 min at 4 °C, the supernatant solution was
incubated with EZview Red anti-FLAG M2 affinity gel over-
night at 4 °C. Gel beads were washed with 20 volumes of co-
immunoprecipitation buffer with rotation at 4 °C for 5 min
each time. Protein was eluted with FLAG peptide (Sigma) fol-
lowing the standard protocol of the manufacturer. The super-
natant solution was mixed with 5 SDS sample loading buffer,
boiled for 5 min, and separated in a 10% Tris-HCl SDS/PAGE
gel (40). The gel was then treated with fixing buffer (50% etha-
nol and 10% acetic acid) for 20 min, and washed with distilled
water for 1 h before being stained with GelCode Blue stain
(Pierce) overnight. The gel was destained with distilled water
for 2 h before analysis by MS.
Protein In-gel Digestion—Pieces cut from SDS/PAGE gels
were excised and subjected to in-gel tryptic digestion. The
excised bands were washed twice with 100 mM ammonium
bicarbonate containing 50% acetonitrile for 1 h and twice with
acetonitrile for 10 min. The proteins in the gels were then
treated with 20 mM DTT at room temperature for 30 min, fol-
lowed by 50 mM iodoacetamide for 30 min in 100 mM ammo-
nium bicarbonate. After the treatment, the reagents were
removed, and the gel pieces were washed with 100 mM ammo-
nium bicarbonate and then dehydrated in acetonitrile. The
dried gel pieces were then reswollen in 50 mM ammonium
bicarbonate containing sequencing-grade modified trypsin for
overnight digestion. Tryptic peptides were extracted from the
gel with 50% acetonitrile in 5% formic acid.
MSAnalysis—The proteolytic digests were analyzed using an
LTQ Orbitrap XL linear ion trap mass spectrometer (Thermo
Fisher Scientific, Waltham, MA) coupled with an Ultimate
3000 HPLC system (Dionex, Sunnyvale, CA). The reverse-
phase C18 column (0.075 150 mm, Dionex) was equilibrated
with 0.1% formic acid/4% acetonitrile (v/v), and the proteolytic
digestswere injected on it. A linear gradient of acetonitrile from
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4% to 40% in water in the presence of 0.1% formic acid over a
period of 45 min was used at a flow rate of 300 nl/min. The
spectra were acquired by data-dependent methods consisting
of a full scan (m/z 400–2000) and then tandem MS on the five
most abundant precursor ions. The previously selected precur-
sor ions were scanned once for 30 s and then excluded for 30 s.
The obtained data were submitted to Mascot software (Matrix
Science, Inc., Boston, MA) to search for phosphorylated resi-
dues on the YBX1 protein. The tandem mass spectra of the
possibly modified peptides were further interpreted manually.
Illumina Microarrays—RNA (250 ng) was reverse-tran-
scribed into cDNA and labeled with biotin-UTP using the Illu-
mina TotalPrep RNA amplification kit (Ambion/Applied Bio-
systems, Foster City, CA). The amount of cDNA was
determined using a NanoDrop spectrophotometer, and the
cDNA quality (size distribution) was further analyzed in a 1%
(w/v) agarose gel. cDNA was hybridized to Illumina Human
Ref-v3 v1 Expression BeadChips and scanned in a BeadArray
reader using standard protocols (Illumina, SanDiego, CA). Illu-
mina’s BeadStudio software was used for data analysis.
IF Experiment—Coverslips were coated with 0.1% sterile gel-
atin for 2 h and dried for 30 min at room temperature. 1 105
cells/well were then seeded onto coverslips in a 24-well plate
and left overnight. Cells were then treated with or without
IL-1 for 1 h to continue with IF experiments. Cells were fixed
with 4% formaldehyde for 30min and then blocked with block-
ing buffer for 10 min at room temperature. Coverslips were
further probed with anti-FLAG antibody for FLAG-tagged
WT-YBX1 or S176A and Alexa Fluor 488 (green) goat anti-
mouse IgG. Before sealing the coverslips, mounting medium
with Hoechst was used to stain the nucleus. The slides were
examined under a Leica DMI6000B series fluorescent micro-
scope with63 magnification.
ConditionedMediumCollection andHumanCytokine ELISA
Arrays—Human cytokine ELISA arrays were purchased from
Signosis, Inc. (Santa Clara, CA). Experiments were carried out
according to the protocol of the manufacturer. HT29 control,
WT-YBX1, and S176A overexpression stable cell lines were
seeded and allowed to grow to 90% confluence and then cul-
tured for 3 days. This medium was then collected by centrifu-
gation and added to specific cytokine capture antibody-pre-
coated wells for 2 h at room temperature. After incubation, the
wells were washed to remove unbound labeled antibodies. The
plate was further detected with HRP luminescent substrate.
The level of expression for each specific cytokine was directly
proportional to the luminescence that was emitted.
qPCR Analyses—RNA samples were purified with TRIzol
(Thermo Fisher Scientific) reagent as described previously (41).
cDNA was made by reverse PCR from total RNA by using the
SuperScript III first-strand synthesis system (Thermo Fisher
Scientific). FastStart Universal SYBR Green Master ROX
(Roche Diagnostics) was used for the qPCR reactions. Primers
were designed by Primer Express 3.0 software.
IPA—Three groups of genes, i.e. S176A or S165A solely reg-
ulated or commonly regulated genes, were analyzed with IPA
analysis. The setting and filter were as follows: reference set:
Ingenuity Knowledge Base (Genes  Endogenous Chemicals);
Relationship to include: Direct and Indirect; Includes Endoge-
nous Chemicals; Filter Summary: Consider only molecules
where species 	 Human OR Rat OR Mouse. The p values for
the enrichment test were calculated using Fisher’s exact test,
right-tailed. Usually the
log10(p) is visualized to the left of the
p value. p 0.05 was considered significant.
Statistical Analysis—Statistical analysis was performed using
Prism 6 software (GraphPad, San Diego, CA). The data repre-
sent the mean  S.D. from three independent experiments. A
two-tailed Student’s t testwas usedwhen comparing twomeans
and to test for significant differences between relative luciferase
activity and relative gene expression in different groups. All
statistics were calculated on triplicate experiments. For all sta-
tistics, p 0.05 was considered statistically significant.
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